C4 Therapeutics IncCCCC
Price$3.14

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $35M-1.5% YoYTTM through 30 Jun 2026
Net Income -$101.4MTTM through 30 Jun 2026
Free Cash Flow -$85.4MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin-313.4%
Operating Margin-290.6%
Net Margin-289.4%

Returns

-40.9%ROE
-29.2%ROA

Balance Sheet Health

Debt / Equity0.23x
Current Ratio5.45x
Net Debt-$237.1Mnet cash position
Cash & Equivalents$78.6M

Quality Metrics

Altman Z-Score-1.10
Piotroski F-Score2 / 9
FCF Margin-243.7%
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'21'22'23'24'25
FY2025: $35.9M
Diluted EPS-$0.91TTM
'21'22'23'24'25
FY2025: $-1.27

Dividend

No dividend

Capital Allocation

Capex Intensity1.5%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.